Live
10x Genomics Blog10x Genomics CRISPR Brain Atlas Collaboration And What It Means For Investors - Yahoo Finance SingaporeWatersIs Waters Corporation Stock Underperforming the Dow? - BarchartWatersIs Waters Corporation Stock Underperforming the Dow? - Yahoo Finance10x Genomics Blog10x Genomics Stumbles Amid Negative Technical Indicators - BitgetFierceBiotechRare disease advocates stage 'funeral' at FDA, demand 4 actions of agency and CongressAgilentAgilent Technologies Inc. stock outperforms competitors despite losses on the day - MarketWatchCellMitochondrial control of glycerolipid synthesis by a PEP shuttleCellFunctional RNA splitting drove the evolutionary emergence of type V CRISPR-Cas systems from transposonsCellDeep-learning-based <em>de novo</em> discovery and design of therapeutics that reverse disease-associated transcriptional phenotypesCellFour centuries of commercial whaling eroded 11,000 years of population stability in bowhead whalesFierceBiotechBeyond seizures: With experimental drug, Stoke aims to restore developmental loss in Dravet syndromeAgilentAxion Cleared Of False Advertising Before Agilent Patent Trial - Law360
Endpoints News Jan 28, 2026

Boehringer Ingelheim takes rare kidney disease drug to Phase 3 despite puzzling mid-stage data

Boehringer Ingelheim takes rare kidney disease drug to Phase 3 despite puzzling mid-stage data

Original
Body unavailable. Use the original source.

Directory

59 All